Go to the list of all blogs
Anna G's Avatar
published in Blogs
Jan 11, 2021
Lululemon (LULU, $365.46) updates forecasts for fiscal Q4

Lululemon (LULU, $365.46) updates forecasts for fiscal Q4

Lululemon Athletic Inc.  updated its fourth quarter earnings and revenue guidance. The athletic apparel retail company said it projects its fiscal fourth quarter earnings to grow at the high end of its mid-single digits expectation of early December. The company expects revenue growth at the high end of its mid-to-high teens expectation.  

Ahead of the group's presentation to the ICR investor conference, CEO Calvin McDonald cited the momentum over the holiday period, and said that the investments in lululemon and MIRROR helped connect with guests both physically and digitally. "We remain confident about our opportunities in 2021 and committed to our Power of Three growth plan.” , added McDonald.

What’s more, Lululemon’s  online sales surged by an annual rate of +93% last quarter, and are expected to offset any declines in physical sales volumes over the fourth quarter. 

Related Ticker: LULU

LULU's RSI Indicator climbs out of oversold territory

The RSI Oscillator for LULU moved out of oversold territory on September 08, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 41 similar instances when the indicator left oversold territory. In of the 41 cases the stock moved higher. This puts the odds of a move higher at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 60 cases where LULU's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where LULU advanced for three days, in of 326 cases, the price rose further within the following month. The odds of a continued upward trend are .

LULU may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on September 04, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on LULU as a result. In of 84 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for LULU turned negative on September 04, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 45 similar instances when the indicator turned negative. In of the 45 cases the stock turned lower in the days that followed. This puts the odds of success at .

LULU moved below its 50-day moving average on September 04, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for LULU crossed bearishly below the 50-day moving average on September 04, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where LULU declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Fundamental Analysis (Ratings)

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. LULU’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.384) is normal, around the industry mean (3.089). P/E Ratio (8.493) is within average values for comparable stocks, (23.252). LULU's Projected Growth (PEG Ratio) (0.798) is slightly lower than the industry average of (1.650). LULU has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.034). P/S Ratio (1.079) is also within normal values, averaging (0.699).

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. LULU’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 89, placing this stock worse than average.

Notable companies

The most notable companies in this group are TJX Companies (NYSE:TJX), lululemon athletica (NASDAQ:LULU), Gap Inc (The) (NYSE:GAP), Abercrombie & Fitch Co (NYSE:ANF), Stitch Fix (NASDAQ:SFIX).

Industry description

Companies in the apparel and/or footwear retail industry sell clothing, accessories and footwear, for different age groups and genders. The industry’s product categories could range from basics, such as underwear, to luxury items. Some retailers source items from wholesalers or an apparel brand to sell in their stores; some others are licensed to make and market their own retail goods under particular brands. Several companies outsource production of clothing to developing/emerging economies where labor costs are relatively inexpensive. Apparel retail is often influenced by fashion trends, and many companies feel the need to adapt to what’s “in vogue” to retain customers and attract new ones. A major disruption in this industry has been the burgeoning trend in digital shopping – to compete with rapidly growing e-commerce, even traditional retail players are upping the ante on their online platforms. Much of the products’ performance in apparel/footwear retail is cyclical, i.e., economic boom times encourage consumer spending, while recessions induce thriftiness among people. Some large-cap U.S. apparel/footwear retail companies include TJX Companies Inc., Ross Stores, Inc., Lululemon Athletica Inc. and Burlington Stores, Inc.

Market Cap

The average market capitalization across the Apparel/Footwear Retail Industry is 8.65B. The market cap for tickers in the group ranges from 256K to 179.95B. IDEXY holds the highest valuation in this group at 179.95B. The lowest valued company is DESTQ at 256K.

High and low price notable news

The average weekly price growth across all stocks in the Apparel/Footwear Retail Industry was -1%. For the same Industry, the average monthly price growth was -14%, and the average quarterly price growth was 5%. DLTH experienced the highest price growth at 22%, while DBGI experienced the biggest fall at -25%.

Volume

The average weekly volume growth across all stocks in the Apparel/Footwear Retail Industry was 39%. For the same stocks of the Industry, the average monthly volume growth was 118% and the average quarterly volume growth was -48%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 45
P/E Growth Rating: 56
Price Growth Rating: 59
SMR Rating: 65
Profit Risk Rating: 88
Seasonality Score: -27 (-100 ... +100)
View a ticker or compare two or three
LULU
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a retailer of athletic apparels

Industry ApparelFootwearRetail

Profile
Details
Industry
Apparel Or Footwear Retail
Address
1818 Cornwall Avenue
Phone
+1 604 732-6124
Employees
39000
Web
https://www.lululemon.com
Interact to see
Advertisement
What if a single trading robot could harvest volatility across semiconductors, oil, and communication technology — simultaneously — while filtering out the noise that burns most active traders? That's exactly what the Semiconductors, Oil & Energy, Communication Tech AI Trading Agent delivers. Over the past 364 days (March 5, 2025 – March 4, 2026), this agent generated a Total Net Profit of $20,641.78 on $500-per-trade sizing — an eye-catching Annualized Return of 68.58%. With 1,534 closed trades, a 61.86% win rate, and a dominant Profit Factor of 3.02
What if an AI trading agent could turn market chaos into a 45.55% annualized return? That's exactly what Tickeron's HUBB, AVGO, ITA, QQQ – AI Trading Agent (4 Tickers, 5min) has delivered across 106 days of live trading — posting $11,605.87 in total net profit from a per-trade allocation of $2,500–$8,250, a 69.59% win rate across 444 closed trades, and a Profit Factor of 2.18.
83.97% Win Rate | 87.10% Annualized Return | $44,879.15 Total Net Profit | Profit Factor: 4.92 | Sharpe Ratio: 1.13
HYMC’s latest sell‑off is part of a broader downtrend that accelerated after the company delayed its PEA, which investors interpreted as an uncertainty event despite no immediate change in reported resources or cash position. Technical indicators such as HYMC breaking above its upper Bollinger Band and then rolling over, along with the Aroon indicator turning down in late February, signaled an elevated risk of a sharp pullback that is now playing out.
DSGR reported quarterly EPS of about 0.18 dollars, badly missing consensus estimates of roughly 0.32–0.33 dollars per share and marking a sharp drop from 0.42 dollars a year ago, which triggered a large negative earnings surprise. Revenue of about 481–482 million dollars came in below expectations near 496 million dollars, and adjusted EBITDA margins compressed to about 7.4% from 9.3% in the prior‑year quarter, highlighting cost and mix pressures.
Shares of CRDO surged +11.90% on March 5, 2026, closing at $114.74 versus a prior close of $102.54. Primary catalyst: Strong Q3 fiscal 2026 earnings reported on March 2, with revenue of $407 million beating consensus estimates by more than $19 million and non-GAAP EPS of $1.07 surpassing forecasts by $0.29.
SPY is trading down approximately -1.30% in Friday premarket, slipping from the prior session's close of $681.31 to around $677–$678. The primary catalyst is a sharply negative February 2026 Nonfarm Payrolls report, which showed a decline of 92,000 jobs — a massive miss versus the consensus forecast of +50,000.
WAL shares dropped approximately 12% in early trading on March 6, 2026, from a prior close of ~$80.74 to roughly ~$71, marking one of the stock's sharpest single-session declines in recent months. The primary catalyst was a surprise announcement that Jefferies Financial Group declined to make a $126.4 million payment owed to Western Alliance Bank under a forbearance agreement tied to the LAM Trade Finance loan portfolio.
MRVL shares surged approximately +15% at the open on March 6, 2026, after closing at $75.68 the prior session. The primary catalyst was a strong Q4 fiscal 2026 earnings report released after the close on March 5, with non-GAAP EPS of $0.80 beating the $0.79 consensus estimate and revenue of $2.219 billion exceeding expectations.
Shares of Day One Biopharmaceuticals surged approximately +65.57% on March 6, 2026, rising from a prior close of $12.78 to an intraday price around $21.16. The primary catalyst driving the session's gains is acquisition and takeover speculation, with reports circulating that Day One may be a buyout target.
GAP shares fell approximately 13% in early trading on March 6, 2026, following the company's Q4 fiscal 2025 earnings report released after market close on March 5. Gap met Wall Street's Q4 estimates on both earnings per share and revenue, but fiscal 2026 guidance fell short of analyst expectations.
Shares of Red Cat Holdings surged approximately +22% in early Friday trading on March 6, 2026, building on a powerful week of momentum in defense drone stocks. The primary catalyst is escalating geopolitical conflict — U.S. and Israeli military strikes on Iran, which dramatically boosted investor appetite for domestic drone and defense technology companies.
The primary catalyst for the decline was the pricing of a secondary offering of roughly 9 million shares at about 22.25 dollars per share by Ingram Holdco, an affiliate of Platinum Equity, with all proceeds going to the selling shareholder and not to Ingram Micro itself. Investors often view such secondary offerings as short‑term bearish because they increase the freely tradable float and signal that a major holder is cashing out part of its stake, even if the company’s operations remain intact.
Rumble reported Q4 2025 revenue of about 27.1 million dollars, below consensus expectations near 29 million dollars and down roughly 10% year over year, confirming that top‑line momentum has stalled. GAAP EPS came in at a loss of around 0.13 dollars, missing analyst estimates by roughly 0.05 dollars and underscoring that the platform remains far from break‑even despite prior cost cuts and efficiency efforts.
Tronox’s Q4 2025 non‑GAAP EPS came in at a loss of about 0.60 dollars, missing expectations by roughly 0.02 dollars, while revenue of around 730 million dollars grew about 8% year over year, showing volume resilience but weak earnings power.
Defense budgets worldwide are surging — global military spending topped $2.2 trillion in 2023, a record high — while semiconductor demand is projected to reach a $1 trillion industry by 2030. At the intersection of these two mega-trends sits one of Tickeron's most strategically focused AI Trading Robots: the XAR, ITA, SOXL – AI Trading Agent (3 Tickers), 15min.
HIMS shares surged approximately +43.85% in premarket trading on Monday, March 9, 2026, rising from a prior close of $15.74 to around $22.80. Primary catalyst: Novo Nordisk officially ended its patent infringement lawsuit against Hims & Hers and announced a landmark partnership to distribute branded Wegovy through the Hims platform at $599/month.
XENE shares surged approximately +45.93% in premarket trading on March 9, 2026, one of the largest single-session moves in the company's history. The primary catalyst: Xenon announced positive topline Phase 3 X-TOLE2 results for its lead drug candidate azetukalner in focal onset seizures (FOS), meeting the primary endpoint with overwhelming statistical significance.
Shares of OLMA dropped approximately 41% in Monday's session, one of the steepest single-day declines in the company's history. The primary catalyst was Roche's Phase 3 persevERA trial failure — a late-stage study of giredestrant, a closely competing selective estrogen receptor degrader (SERD), which missed its primary endpoint of statistically significant improvement in progression-free survival.
RLMD shares surged approximately +40% at the open on March 9, 2026, rising from a prior close of $4.45 to approximately $6.23, driven by a major clinical trial readout. The primary catalyst was the announcement of 12-month interim data from the Phase 2 trial of NDV-01, Relmada's lead oncology candidate, in patients with high-risk non-muscle invasive bladder cancer (NMIBC) — results that significantly exceeded historical benchmarks.